Compare RYTM & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | G |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | RYTM | G |
|---|---|---|
| Price | $102.78 | $37.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $129.92 | $49.50 |
| AVG Volume (30 Days) | 657.2K | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.98 | $8.88 |
| Revenue Next Year | $56.07 | $7.47 |
| P/E Ratio | ★ N/A | $12.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.91 | $34.79 |
| 52 Week High | $122.20 | $55.50 |
| Indicator | RYTM | G |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 33.37 |
| Support Level | $95.44 | $34.79 |
| Resistance Level | $110.93 | $41.00 |
| Average True Range (ATR) | 5.61 | 1.81 |
| MACD | -0.53 | -0.42 |
| Stochastic Oscillator | 48.51 | 27.92 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.